Paritaprevir
产品说明书
 |
同义名 : | Veruprevir; ABT-450 |
| CAS号 : | 1216941-48-8 | |
| 货号 : | A489510 | |
| 分子式 : | C40H43N7O7S | |
| 纯度 : | 99%+ | |
| 分子量 : | 765.88 | |
| MDL号 : | MFCD28411394 | |
| 存储条件： |
Pure form Inert atmosphere, store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 120 mg/mL(156.68 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Hepatitis C virus (HCV) infection is a major health problem that affects about 3% of the world's population. Chronic infection can evolve into cirrhosis, end-stage liver disease and hepatocellular carcinoma[3]. Paritaprevir is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively[4]. Paritaprevir demonstrates in vitro antiviral activity against HCV GT1-4 and GT6 (EC50 range, 0.09 to 19 nM), with an EC50 of 0.09 nM against GT4a[5]. The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections[4]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.31mL 0.26mL 0.13mL |
6.53mL 1.31mL 0.65mL |
13.06mL 2.61mL 1.31mL |
| 参考文献 |
|---|